期刊文献+

多囊卵巢综合征患者对氧磷酶1基因-108 C/T多态性的研究 被引量:1

The-108 C/T Polymorphism in Paraoxonase 1 Gene in Chinese Patients with Polycystic Ovary Syndrome
原文传递
导出
摘要 目的研究对氧磷酶1基因(PON1)调控区-108位点C/T多态性是否与中国妇女多囊卵巢综合征(PCOS)有关联,为阐明PCOS的分子遗传基础提供依据。方法应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术对中国成都地区346例PCOS患者和315例对照妇女PON1基因-108位点C/T多态性进行了分析。用化学发光法测定血清总睾酮(TT)、黄体生成素(LH)、促卵泡激素(FSH)和血浆胰岛素(INS);用酶法试剂盒测定血糖(GLU)、总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C);用微量丙二醛测定试剂盒测定血清丙二醛(MDA)浓度。结果 PCOS组PON1基因-108位点CC、CT、TT基因型频率分别为:0.283、0.517、0.199,C和T等位基因频率分别为:0.542和0.458;对照组该位点CC、CT、TT基因型频率分别为:0.324、0.492、0.184,C和T等位基因频率分别为:0.570和0.430,两组间基因型和等位基因频率差异无统计学意义(P>0.05)。在对照组,CT基因型亚组F-G评分和餐后2h血糖(GLU120)水平高于CC基因型亚组(P<0.05),TT基因型亚组FSH水平和血清MDA浓度高于CC基因型亚组(P<0.05),在调整了年龄和BMI以后,FSH、GLU120和MDA的差异仍然有统计学意义(P=0.006、0.033和0.047)。在PCOS患者组,CT基因型亚组动脉硬化指数(AI)高于CC基因型亚组(P=0.038),但在调整年龄和BMI以后,差异不再有统计学意义(P=0.053)。结论 PON1基因调控区-108位点C/T多态性与对照妇女糖代谢、生殖激素水平及氧化应激有一定关联性,但未发现该位点与中国成都地区PCOS的发病有关。 Objective To investigate the relationship between the-108 C/T polymorphism in the promoter of paraoxonase 1(PON1) gene and polycystic ovarian syndrome(PCOS) in Chinese women.Methods A total of six hundred and sixty one subjects(346 patients with PCOS and 315 healthy control women) in Chengdu area were included in this study.The-108 C/T polymorphism in PON1 gene wasstudied using polymerase chain reaction and restriction fragment length polymorphism analysis(PCR-RFLP).Total testosterone(TT),luteinizing hormone(LH),follicle stimulating hormone(FSH) and plasma insulin(INS) were determined by chemiluminescent method.Plasma glucose(GLU),total cholesterol(TC),triglycerides(TG),high density lipoprotein cholesterol(HDL-C),and low density lipoprotein cholesterol(LDL-C) were measured by enzymatic assay.Serum malondialdehyde(MDA) levels were measured by spectrophometry at 532 nm using micro-MDA detection kits.Results The frequencies of CC,CT and TT genotypes at PON1-108 C/T site in PCOS and control groups were 0.283 and 0.324,0.517 and 0.492,0.199 and 0.184,respectively,and the frequencies of C and T alleles in both groups were 0.542 and 0.570,0.458 and 0.430,respectively.There were no significant differences in the frequencies of the genotypes and alleles between PCOS and control groups(P〉0.05).In the control group,the subjects with genotype CT had higher F-G scores and plasma glucose levels at 2 h during OGTT(75 g glucose) when compared with those of genotype CC(P〈0.05).Higher FSH level and MDA concentration also observed in those of genotype TT by compared with those of CC genotype(P〈0.05).The differences in FSH,GLU120 and MDA levels remained significant after adjustment for age and BMI(P=0.006,0.033 and 0.047,respectively).In the PCOS group,the patients with genotype CT had higher atherogenic index(AI) when compared with those of genotype CC(P=0.038),but this difference was not significant after adjustment for age and BMI(P=0.053).Conclusion This study indicated that the-108 C/T polymorphism in the promoter of PON1 gene was associated with hormonal levels,glucose metabolism and oxidative stress in the control women,but not associated with PCOS in Chinese women of Chengdu area.
出处 《四川大学学报(医学版)》 CAS CSCD 北大核心 2011年第1期24-28,共5页 Journal of Sichuan University(Medical Sciences)
基金 教育部回国人员启动基金(20071108-18-3) 四川省科学研究基金(2008SZ0029)资助
关键词 对氧磷酶1 基因多态性 多囊卵巢综合征 氧化应激 Paraoxonase 1 Gene polymorphism Polycystic ovary syndrome Oxidative stress
  • 相关文献

参考文献14

  • 1Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci,2009;46(2):83-106.
  • 2Escobar-Morreale HF, Luque-Ramirez M, San Millan JL. The molecular-genetic basis of functional layperandrogenism and the polycystic ovary syndrome. Endocr Rev,2005,26(2) :251-282.
  • 3Fenkci IV, Serteser M, Fenkci S, et al. Paraoxonase levels in women with polycystic ovary syndrome. J Reprod Med, 2007,52(10) : 879-883.
  • 4Dursun P, Demirtas E, Bayrak A, et al. Decreased serum paraoxonase 1 (PON1) activity: an additional risk factor for atherosclerotic heart disease in patients with PCOS? Hum Reprod, 2006 ; 21 (1) : 104-108.
  • 5San Millan JL, Corton M, Villuendas G, et al. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab, 2004, 89 ( 6 ) : 2640-2646.
  • 6The Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polyeystie ovary syndrome. Fertil Steri, 2004 ; 81 ( l ) : 19-25.
  • 7李游,范平,白怀,万德花,刘宏伟.PCOS患者PAF-AH活性及其与糖脂代谢相关性的研究[J].四川大学学报(医学版),2009,40(6):1066-1070. 被引量:10
  • 8万德花,范平,白怀,宋琪,刘宏伟.多囊卵巢综合征患者血浆中不同结合状态的血小板活化因子乙酰水解酶活性与胰岛素抵抗的关系[J].中华妇产科杂志,2010,45(1):30-34. 被引量:15
  • 9Erlich HA. Principles and applications for DNA amplification. In:Higuchi R. 1st ed. PCR technology. New York: Stockton Press,1989:36.
  • 10Brophy VH, Jampsa RL, Clendenning JB, et al. Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet,2001 ;68(6) :1428-1436.

二级参考文献30

  • 1胡卫红,乔杰,王黎娜,同军.多囊卵巢综合征患者血清C反应蛋白与单核细胞趋化因子蛋白-1的相关性[J].武警医学,2007,18(7):504-508. 被引量:5
  • 2Valkenburg O, Steegers-Theunissen RP, Smedts HP, etal. A more atherogenlc serum lipoprotein profile is present in women with polycystie ovary syndrome: a case-control study. J Clin Endocrinol Metab,2008;93(2) :470-476.
  • 3Diamanti-Kandarakis E, Alexandraki K, Piperi C, et al. Inflammatory and endothelial markers in women with polyeystic ovary syndrome. Eur J Clin Invest, 2006 ; 36 (10) : G91-697.
  • 4Palacio JR, Iborra A, Ulcova-Gallova Z, et al. The presence of antibodies to oxidative modified proteins in serum from polycystic ovary syndrome patients. Clin Exp Immunol, 2006 144(2) :217-222.
  • 5Shroff R, Kerchner A, Maifeld M, et al. Young obese women with polycystic ovary syndrome have evidence of early coronary atheroselerosis. J Clin Endocrinol Metab, 2007 ; 92 (12) : 4609- 4614.
  • 6Castro Faria Neto HC, Stafforini DM, Prescott SM, et al. Regulating inflammation through the anti-inflammatory enzyme platelet-aetivating factor-aeetylhydrolase. Mere Inst Oswaldo Cruz,2005 ,100(Suppl 1) :83-91.
  • 7Navab M, Ananthramaiah GM, Reddy ST, et al. The oxidation hypothesis of atherogenesis:the role of oxidized phospholipids and HDL. J Lipid Res,2004,45(6):7993-1007.
  • 8Karasawa K. Clinical aspects of plasma platelet-activating factor-acetylhydrolase. Bioehim Biophys Aeta,2006,1761(11): 1359-1372.
  • 9Takasaki Y. Serum lipid levels and factors affecting atherogenie index in Japanese chiidren. J Physioi Anthropol Appl Human Sei,2005 ;24(4) :511-515.
  • 10Zhang B, Fan P, Shimoji E, et al. Modulating effects of cholesterol feeding and simvastatin treatment on plateletactivating factor acetylhydrolase activity and lysophosphatldylcholine concentration. Atherosclcrosis, 2006, 186(2) : 291-301.

共引文献22

同被引文献51

  • 1Li R, Zhang Q, Yang D, et al. Prevalence of polycystic ovary syndrome in women in china: a large community-based study[J]. Hum Reprod, 2013, 28(9):2562-Z569.
  • 2The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome [J]. FertilSteril, 2004, 81(1) :19-25.
  • 3Murri M, Luque-Ramirez M, Insenser M, et al. Circulating markers of oxidative stress and polycystic ovary syndrome (PCOS) : a systematic review and meta-analysis[J]. Hum Reprod Update, 2013,19(3) :268-288.
  • 4Zhang J, Fan P, Liu H, et al. Apolipoprotein A-I and B levels, dyslipidemia and metabolic syndrome in south-west chinese women with PCOS[J]. Hum Reprod, 2012,27(8):2484-2493.
  • 5Lim SS, Davies MJ, Norman RJ, et al. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis[J]. Hum Reprod Update, 2012,18(6) : 618-637.
  • 6de Groot PC, Dekkers OM, Romijn JA, et al. PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis[,J]. Hum Reprod Update, 2011,17(4): 495-500.
  • 7Moran LJ, Misso ML, Wild RA, et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis[,J]. Hum Reprod Update, 2010, 16(4) :347-363.
  • 8Precourt LP, Amre D, Denis MC, et al. The three-gene paraoxonase family: physiologic roles, actions and regulation[J]. Atherosclerosis, 2011,214 ( 1 ) : 20-36.
  • 9Perla-Kajan J, Jakubowski H. Paraoxonase 1 and homocysteine metabolism[J]. Amino acids, 2012, 43(4) : 1405-1417.
  • 10Camps J, Marsiltach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement[J']. Crit Rev Clin Lab Sci, 2009, 46(2) :83-106.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部